ELVN - Enliven Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$69.50
DETAILS
HIGH:
$80.00
LOW:
$59.00
MEDIAN:
$69.50
CONSENSUS:
$69.50
UPSIDE:
67.31%
About Enliven Therapeutics, Inc. (https://www.enliventherapeutics.com)
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Samuel S. Kintz | Co-Founder & Head of Pipeline | 1986 | $956,094 USD |
| Helen Louise Collins | Chief Medical Officer | 1963 | $726,420 USD |
| Joseph Lyssikatos | Co-Founder & Chief Scientific Officer | 1965 | $709,400 USD |
| Richard A. Fair | CEO, President & Director | 1969 | $672,656 USD |
| Benjamin Hohl | Chief Financial Officer & Head of Corporate Development | 1989 | $667,894 USD |
| Anish Patel | Co-Founder & Chief Operating Officer | 1981 | – |
| Galya D. Blachman | Chief Legal Officer & Head of Business Development | 1977 | – |